CL2021000514A1 - Dimetilaminoazetidinaminas como inhibidores de jak - Google Patents

Dimetilaminoazetidinaminas como inhibidores de jak

Info

Publication number
CL2021000514A1
CL2021000514A1 CL2021000514A CL2021000514A CL2021000514A1 CL 2021000514 A1 CL2021000514 A1 CL 2021000514A1 CL 2021000514 A CL2021000514 A CL 2021000514A CL 2021000514 A CL2021000514 A CL 2021000514A CL 2021000514 A1 CL2021000514 A1 CL 2021000514A1
Authority
CL
Chile
Prior art keywords
dimethylaminoazetidinamines
compounds
jak inhibitors
provides
variables
Prior art date
Application number
CL2021000514A
Other languages
English (en)
Inventor
Cameron Smith
Daniel D Long
Corbin Thompson
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2021000514A1 publication Critical patent/CL2021000514A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos de la fórmula (I): donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable de estas, que son útiles como inhibidores de la cinasa JAK. La invención también proporciona composiciones farmacéuticas que comprenden dichos compuestos, y métodos de uso de dichos compuestos para tratar las enfermedades respiratorias.
CL2021000514A 2018-09-04 2021-03-02 Dimetilaminoazetidinaminas como inhibidores de jak CL2021000514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726562P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
CL2021000514A1 true CL2021000514A1 (es) 2021-07-23

Family

ID=67982186

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000514A CL2021000514A1 (es) 2018-09-04 2021-03-02 Dimetilaminoazetidinaminas como inhibidores de jak

Country Status (27)

Country Link
US (4) US10947229B2 (es)
EP (1) EP3837258B1 (es)
JP (2) JP7324836B2 (es)
KR (1) KR102826491B1 (es)
CN (1) CN112739697B (es)
AR (1) AR116115A1 (es)
AU (1) AU2019336167B2 (es)
BR (1) BR112021004052A2 (es)
CL (1) CL2021000514A1 (es)
CO (1) CO2021002977A2 (es)
DK (1) DK3837258T3 (es)
EA (1) EA202190681A1 (es)
ES (1) ES2982858T3 (es)
FI (1) FI3837258T3 (es)
HR (1) HRP20241002T1 (es)
HU (1) HUE068058T2 (es)
IL (1) IL281146B2 (es)
LT (1) LT3837258T (es)
MA (1) MA53229A (es)
MX (1) MX2021002521A (es)
PH (1) PH12021550368A1 (es)
PL (1) PL3837258T3 (es)
PT (1) PT3837258T (es)
SG (1) SG11202101734RA (es)
SI (1) SI3837258T1 (es)
TW (1) TWI791886B (es)
WO (1) WO2020051105A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6800969B2 (ja) 2015-11-03 2020-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 呼吸器疾患の処置のためのｊａｋキナーゼ阻害剤化合物
MX388750B (es) 2017-03-09 2025-03-20 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
JP7324836B2 (ja) * 2018-09-04 2023-08-10 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としてのジメチルアミノアゼチジンアミド
TWI808250B (zh) 2018-09-04 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 用於製備jak抑制劑之方法及其中間體
EA202190686A1 (ru) 2018-09-04 2021-07-23 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи 5-7-членные гетероциклические амиды в качестве ингибиторов jak
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN115803023A (zh) * 2020-05-08 2023-03-14 施万生物制药研发Ip有限责任公司 发用奈珠西替尼治疗感染冠状病毒的患者的方法
WO2022271604A1 (en) 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
WO2022272020A1 (en) * 2021-06-25 2022-12-29 Theravance Biopharma R&D Ip, Llc Imidazolo indazole compounds as jak inhibitors
MX2024007477A (es) * 2021-12-17 2024-07-09 Daewoong Pharmaceutical Co Ltd Nueva sal de adicion de acido y forma cristalina de (2r,3s)-2-(3-(4,5-dicloro-1h-benzo[d]imidazol-1-il)propil)piperid in-3-ol.
JP2025515078A (ja) 2022-05-05 2025-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 噴霧経口吸入による送達のためのネズルシチニブ
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
JP5651681B2 (ja) 2009-04-03 2015-01-14 大日本住友製薬株式会社 代謝型グルタミン酸受容体５介在障害の治療のための化合物、およびその使用方法
ES2652287T3 (es) 2009-12-21 2018-02-01 Samumed, Llc 1H-pirazol [3,4-b] piridinas y usos terapéuticos de las mismas
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PE20161246A1 (es) 2013-12-05 2016-11-25 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
ES2737696T3 (es) 2014-05-14 2020-01-15 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
ES2840650T3 (es) 2015-11-03 2021-07-07 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
JP6800969B2 (ja) * 2015-11-03 2020-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 呼吸器疾患の処置のためのｊａｋキナーゼ阻害剤化合物
ES2864035T3 (es) 2015-11-03 2021-10-13 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
MX388750B (es) 2017-03-09 2025-03-20 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
MX388748B (es) 2017-05-01 2025-03-20 Theravance Biopharma R&D Ip Llc Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
TWI808083B (zh) 2017-05-01 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶型式
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
US11878270B2 (en) 2018-07-20 2024-01-23 Porifera, Inc. Osmosis modules having recirculation loops
TWI808250B (zh) 2018-09-04 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 用於製備jak抑制劑之方法及其中間體
JP7324836B2 (ja) 2018-09-04 2023-08-10 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としてのジメチルアミノアゼチジンアミド
EA202190686A1 (ru) 2018-09-04 2021-07-23 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи 5-7-членные гетероциклические амиды в качестве ингибиторов jak
AU2019373059A1 (en) 2018-10-29 2021-05-06 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane compound as JAK inhibitor
IL285783B2 (en) 2019-02-25 2024-12-01 Henan Medinno Pharmaceutical Tech Co Ltd Jak inhibitor compound and use thereof
JP2022524997A (ja) 2019-03-05 2022-05-11 インサイト・コーポレイション 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN115803023A (zh) 2020-05-08 2023-03-14 施万生物制药研发Ip有限责任公司 发用奈珠西替尼治疗感染冠状病毒的患者的方法
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
TW202304902A (zh) 2021-03-26 2023-02-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之二鹽酸鹽之結晶形式
WO2022271604A1 (en) * 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Also Published As

Publication number Publication date
JP2021535177A (ja) 2021-12-16
WO2020051105A1 (en) 2020-03-12
US20250034131A1 (en) 2025-01-30
DK3837258T3 (da) 2024-07-22
CO2021002977A2 (es) 2021-05-31
HRP20241002T1 (hr) 2024-10-25
SI3837258T1 (sl) 2024-09-30
US20200071323A1 (en) 2020-03-05
ES2982858T3 (es) 2024-10-17
JP2022172299A (ja) 2022-11-15
US11634419B2 (en) 2023-04-25
SG11202101734RA (en) 2021-03-30
US20210155620A1 (en) 2021-05-27
MA53229A (fr) 2022-05-11
PH12021550368A1 (en) 2022-03-28
KR102826491B1 (ko) 2025-06-27
EP3837258A1 (en) 2021-06-23
EA202190681A1 (ru) 2021-05-28
AR116115A1 (es) 2021-03-31
AU2019336167B2 (en) 2024-08-29
US20230322774A1 (en) 2023-10-12
CN112739697A (zh) 2021-04-30
CN112739697B (zh) 2023-10-20
AU2019336167A1 (en) 2021-03-11
BR112021004052A2 (pt) 2021-05-25
KR20210056381A (ko) 2021-05-18
US12398135B2 (en) 2025-08-26
LT3837258T (lt) 2024-05-27
HUE068058T2 (hu) 2024-12-28
PT3837258T (pt) 2024-06-20
PL3837258T3 (pl) 2024-09-16
MX2021002521A (es) 2021-04-28
FI3837258T3 (fi) 2024-05-27
IL281146B1 (en) 2023-08-01
TWI791886B (zh) 2023-02-11
TW202024073A (zh) 2020-07-01
US10947229B2 (en) 2021-03-16
IL281146B2 (en) 2023-12-01
IL281146A (en) 2021-04-29
JP7324836B2 (ja) 2023-08-10
EP3837258B1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
CL2020001090A1 (es) Compuesto de pirimidina como inhibidor de las janocinasas.
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201791576A1 (ru) Ингибитор jak
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
BR112021011325A2 (pt) Derivados de rapamicina
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы